|
Volumn 21, Issue 1 A, 2001, Pages 23-28
|
Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents
a a a a a a a a a a a a a a a |
Author keywords
Chemotherapy sensitization; Chk1; G2 abrogation; Staurosporine; UCN01
|
Indexed keywords
7 HYDROXYSTAUROSPORINE;
ANTINEOPLASTIC AGENT;
CELL CYCLE PROTEIN;
DOXORUBICIN;
PROTEIN P53;
STAUROSPORINE;
ARTICLE;
CANCER CHEMOTHERAPY;
CELL CYCLE G2 PHASE;
CELL DEATH;
CELL TRANSFORMATION;
CONTROLLED STUDY;
CYTOTOXICITY;
DNA DAMAGE;
GENE INACTIVATION;
HUMAN;
HUMAN CELL;
PRIORITY JOURNAL;
ALKALOIDS;
ANTINEOPLASTIC AGENTS;
APOPTOSIS;
CELL LINE, TRANSFORMED;
DNA DAMAGE;
DOXORUBICIN;
ENZYME INHIBITORS;
G2 PHASE;
HUMANS;
NEOPLASMS;
PROTEIN KINASES;
STAUROSPORINE;
TUMOR CELLS, CULTURED;
TUMOR SUPPRESSOR PROTEIN P53;
|
EID: 0035062416
PISSN: 02507005
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (37)
|
References (25)
|